|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.320 CAD | -2.77% |
|
-2.77% | -5.67% |
| Apr. 06 | InnoCan Pharma Corporation announced that it has received $0.2 million in funding | CI |
| Mar. 31 | InnoCan Pharma Corporation announced that it expects to receive $0.2 million in funding | CI |
Main competitors
| Revenues (N-1) | Net Margin (N-1) | EBIT Margin (N-1) | ROE (N-1) | ROA (N-1) | Leverage (N-1) | ||
|---|---|---|---|---|---|---|---|
 | 65.18B | 31.67% | 41.84% | 106.69% | 22.77% | 1.2x | |
| 94.19B | 28.46% | 32.23% | 31.68% | 13.82% | 0.84x | |
| 61.16B | 6.91% | 38.79% | 64,669.09% | 13.22% | 2.44x | |
| 77.58B | 20.94% | 35.49% | 47.65% | 15.43% | 0.66x | |
| 58.74B | 17.41% | 31.46% | 31.99% | 13.12% | 1.2x | |
| 56.67B | 24.64% | 38.62% | 38.4% | 16.33% | 1.02x | |
| 65.01B | 28.08% | 41.19% | 45.52% | 17.73% | 1.07x | |
| 36.75B | 20.98% | 44.09% | 162.88% | 12.98% | 2.13x | |
| 48.59B | 33.14% | 41.3% | 60.7% | 20.31% | 0.69x | |
| 29.44B | 28.9% | 44.81% | 48.87% | 17.34% | 1.08x | |
| 62.58B | 12.42% | 35.11% | 21.07% | 8.73% | 1.79x | |
| 48.19B | 14.64% | 30.37% | 72.08% | 7.72% | 1.83x | |
| 51.22B | 17.91% | 27.85% | 10.5% | 6.02% | 0.81x | |
| 43.97B | 17.5% | 29.95% | 46.39% | 9.48% | 1.28x | |
| 12B | 32.94% | 43.85% | 27.07% | 16.41% | -1.21x | |
| 8.02B | 34.5% | 47.6% | 22.1% | 25.56% | -0.66x | |
| 30.6B | 2.36% | 7.48% | 1.5% | 1.19% | 3.6x | |
| 4.52B | 24.38% | 28.42% | 14.26% | 12.85% | -4.14x | |
| 53.51B | -7.94% | 11.21% | 16.66% | -3.36% | 4.79x | |
| Average | 47.79B | 20.52% | 34.3% | 3,446.06% | 13.03% | 1.08x | |
| Weighted average by Cap. | 59.75B | 23.42% | 37.06% | 5,520.88% | 15.58% | 1.14x |
- Stock Market
- Equities
- INNO Stock
- Sector InnoCan Pharma Corporation
- Financial comparisons
Select your edition
All financial news and data tailored to specific country editions
